Dr. Boz [Annette Bosworth, MD] - The #1 supplement to reverse fatty liver

Short Summary

Main recommendation: Low-dose aspirin (81 mg) may help reduce liver fat and fibrosis in people with fatty liver disease, based on a 6-month randomized trial of 80 patients. The speaker also argues aspirin has broader benefits, including lower cancer mortality in older regular users, while its bleeding risk appears small.

Key Points

• In a randomized, double-blinded, placebo-controlled trial of 80 patients with MASLD (fatty liver disease caused by a broken metabolism), 81 mg aspirin reduced liver fat over 6 months while placebo slightly increased it.
• Using MRI-based tools (magnetic resonance spectroscopy and MRI proton density fat fraction), 43% of the aspirin group reduced liver fat by at least 30%, versus 13% of the placebo group.
• Aspirin also improved inflammatory markers (AST and ALT) and reduced fibrosis scores on MRI, which the speaker calls important because fibrosis is the danger when fatty liver becomes irreversible.
• In a study of over 146,000 older adults over more than a decade, taking aspirin at least three times a week was associated with a 15% lower risk of dying from any cancer, 25% lower risk of GI cancers, and 29% lower risk of colorectal cancer.
• The speaker argues current cardiovascular guidelines address primary prevention only and ignore secondary prevention (people who already have heart disease, a prior heart attack or stroke, or plaque), where the evidence for aspirin is stronger.

Details Worth Noting

• Concrete instructions: The transcript gives no step-by-step dosing schedule or preparation method for aspirin use. The only dosage mentioned is 81 mg, and the speaker's closing promise to show three lifestyle interventions that reverse fatty liver is not explained within the transcript. Any decision about aspirin should be discussed with a qualified clinician, since this is health-related and not professional advice.
• The 6-month fatty liver trial reported no GI bleeds; only one participant reported mild heartburn.
• A meta-analysis of 11 randomized trials found internal bleeding risk of 8 in 10,000 with aspirin versus 5 in 1,000 with placebo, an absolute risk of roughly 0.3%.
• If a GI bleed did occur, the speaker says death risk from that bleed was 50% lower in those taking aspirin.
• Per current guidelines as described by the speaker, aspirin for primary prevention is individualized for ages 40 to 59 and generally not recommended for those older.
• The speaker notes metabolic disease is far more common than heart disease, and that metabolic disease is a prerequisite for heart disease.

Bottom Line

Aspirin is presented as a low-cost option with promising liver, cancer, and heart-related benefits, with bleeding risk described as small, but the speaker's conclusions rest on a small liver trial and observational cancer data, and the transcript should be weighed with a clinician's advice.